Claims for Patent: 10,654,844

Summary for Patent: 10,654,844

Title:	Dual mechanism inhibitors for the treatment of disease
Abstract:	Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
Inventor(s):	deLong; Mitchell A. (Chapel Hill, NC), Sturdivant; Jill Marie (Chapel Hill, NC), Royalty; Susan M. (Davis, CA)
Assignee:	Aerie Pharmaceuticals, Inc. (Bedminster, NJ)
Application Number:	16/435,254
Patent Claims:	1. A pharmaceutically acceptable salt of ##STR00230## ##STR00231## ##STR00232## ##STR00233## ##STR00234## ##STR00235## 2. A composition, comprising the pharmaceutically acceptable salt of claim 1. 3. A pharmaceutical composition, comprising the pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable carrier. 4. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is saline buffered to a pH of about 5.5 to about 6.5. 5. A method of treating an eye disease in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutically acceptable salt of claim 1. 6. The method of claim 5, wherein the eye disease comprises glaucoma. 7. The method of claim 5, wherein the eye disease comprises wet age-related macular degeneration, dry age-related macular degeneration, or diabetic macular edema. 8. The method of claim 5, wherein the eye disease comprises dry eye. 9. The method of claim 5, wherein the eye disease comprises ocular hypertension. 10. The method of claim 5, wherein the administration is topical administration to an eye of the subject. 11. A method of treating an eye disease in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 2. 12. The method of claim 11, wherein the eye disease comprises glaucoma. 13. The method of claim 11, wherein the eye disease comprises wet age-related macular degeneration, dry age-related macular degeneration, or diabetic macular edema. 14. The method of claim 11, wherein the eye disease comprises dry eye. 15. The method of claim 11, wherein the eye disease comprises ocular hypertension. 16. The method of claim 11, wherein the administration is topical administration to an eye of the subject. 17. A method of treating an eye disease in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 3. 18. The method of claim 17, wherein the eye disease comprises glaucoma. 19. The method of claim 17, wherein the eye disease comprises wet age-related macular degeneration, dry age-related macular degeneration, or diabetic macular edema. 20. The method of claim 17, wherein the eye disease comprises dry eye. 21. The method of claim 17, wherein the eye disease comprises ocular hypertension. 22. The method of claim 17, wherein the administration is topical administration to an eye of the subject. 23. A method of treating an eye disease in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 4. 24. The method of claim 23, wherein the eye disease comprises glaucoma. 25. The method of claim 23, wherein the eye disease comprises wet age-related macular degeneration, dry age-related macular degeneration, or diabetic macular edema. 26. The method of claim 23, wherein the eye disease comprises dry eye. 27. The method of claim 23, wherein the eye disease comprises ocular hypertension. 28. The method of claim 23, wherein the administration is topical administration to an eye of the subject.